aDivision of Cardiology, Department of Internal Medicine bDepartment of Medical Research and Education, Taipei Veterans General Hospital cInstitute of Clinical Medicine dCardiovascular Research Center eInstitute and Department of Pharmacology, National Yang-Ming University, Taipei, Taiwan.
J Hypertens. 2013 Nov;31(11):2187-94. doi: 10.1097/HJH.0b013e3283641023.
The increase in pulse pressure (PP) may be transmitted to the glomerulus and thus impair renal blood flow autoregulation. This subtle change could predispose patients to the detrimental effect of contrast media. We sought to determine whether elevated central PP is associated with increased contrast-induced nephropathy (CIN) and future cardiovascular events in patients undergoing percutaneous coronary intervention (PCI).
In total, 448 consecutive patients receiving PCI were enrolled. In each patient, central and peripheral blood pressures were measured before PCI. The occurrence of CIN was identified and defined as a rise in serum creatinine of 0.5 mg/dl or a 25% increase from the baseline value within 48 h after the procedure. All patients were then followed up for at least 3 years or until the occurrence of a major adverse cardiovascular event (MACE) including death, nonfatal myocardial infarction, and ischemic stroke after coronary intervention.
Overall, CIN occurred in 52 (11.6%) patients. Patients developing CIN had higher baseline central PP (P = 0.004). Patients were then stratified into three groups (low/intermediate/high) according to baseline central PP. Compared to that with the lowest tertile of central PP, patients with the highest tertile of central PP had a significantly increased incidence of CIN after PCI (odds ratio, 2.94; 95% confidence interval, CI 1.02-8.51). By Cox regression analysis, elevated central PP was an independent predictor of future MACE in all patients undergoing PCI (hazard ratio, 2.07; 95% CI 1.04-4.12).
Elevated baseline central PP was associated with an increased risk of CIN and future cardiovascular events in patients with PCI. Further clinical study may be indicated to determine whether pharmacological modulation on baseline central PP could prevent CIN and future MACE after PCI.
脉压(PP)升高可能会传递到肾小球,从而损害肾血流自动调节。这种细微的变化可能使患者易受对比剂的不良影响。我们试图确定接受经皮冠状动脉介入治疗(PCI)的患者,中心 PP 升高是否与对比剂诱导的肾病(CIN)和未来心血管事件相关。
共纳入 448 例接受 PCI 的连续患者。在每位患者 PCI 前测量中心和外周血压。确定 CIN 的发生,并将其定义为术后 48 小时内血清肌酐升高 0.5mg/dl 或比基线值升高 25%。所有患者随后至少随访 3 年或直至发生主要不良心血管事件(MACE),包括死亡、非致死性心肌梗死和经皮冠状动脉介入治疗后的缺血性卒中。
总体而言,52 例(11.6%)患者发生 CIN。发生 CIN 的患者基线中心 PP 更高(P=0.004)。根据基线中心 PP 将患者分为三组(低/中/高)。与最低三分位的中心 PP 相比,中心 PP 最高三分位的患者 PCI 后 CIN 的发生率显著增加(优势比,2.94;95%置信区间,1.02-8.51)。通过 Cox 回归分析,在所有接受 PCI 的患者中,升高的中心 PP 是未来 MACE 的独立预测因素(风险比,2.07;95%置信区间,1.04-4.12)。
基线中心 PP 升高与 PCI 患者 CIN 和未来心血管事件的风险增加相关。可能需要进一步的临床研究来确定对基线中心 PP 的药物调节是否可以预防 PCI 后 CIN 和未来的 MACE。